[Plasma levels of D-dimer and von Willebrand factor and the therapeutic effect of compound glycyrrhizin in children with cytomegalovirus hepatitis].
OBJECTIVE
To study the significance of plasma D-dimer and von Willebrand factor (vWF) and the therapeutic effect of compound glycyrrhizin in children with cytomegalovirus (CMV) hepatitis.


METHODS
Twenty healthy children, 16 asymptomatic cases with CMV infection and 52 cases of CMV hepatitis (21 cholestatic and 31 non-cholestatic) were enrolled. The 52 children with CMV hepatitis were randomly administered with conventional treatment alone or conventional treatment plus compound glycyrrhizin treatment. Plasma D-dimer and vWF levels were measured before and after treatment.


RESULTS
Plasma D-dimer and vWF levels in the CMV hepatitis group were markedly higher than those in the healthy control and asymptomatic CMV infection groups (P<0.01). The cholestatic hepatitis group had more increased plasma D-dimer and vWF levels compared with the non-cholestatic hepatitis group (P<0.01). Plasma D-dimer and vWF levels in the CMV hepatitis group were markedly reduced after conventional or compound glycyrrhizin treatment (P<0.01). Compound glycyrrhizin treatment decreased more significantly plasma D-dimer and vWF levels compared with the conventional treatment in children with CMV hepatitis (P<0.01).


CONCLUSIONS
The detection of plasma D-dimer and vWF is useful in the early assessment of liver damage in children with CMV hepatitis. Compound glycyrrhizin can decrease obviously plasma D-dimer and vWF levels and might thus provide protective effects against liver damage.
Shi
Hai-Fan
HF
Department of Infection,Yuying Children's Hospital Affiliated to Wenzhou Medical College, Wenzhou, Zhejiang 325027, China. shf2008@163.com
Chen
Yi-Ping
YP
DI
Jun-Bo
JB
Xu
Zhi-Wei
ZW
D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D019695:Glycyrrhizic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D006525:Hepatitis, Viral, Human / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007223:Infant; D008102:Liver Circulation; D008297:Male; D014841:von Willebrand Factor / Q000032:analysis*
D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D014841:von Willebrand Factor; D019695:Glycyrrhizic Acid